文献速递认知障碍与痴呆

双种族人群样本中临床阿尔茨海默病血液生物标志物的纵向变化

Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample.
PubMed 文献 · Neurology · 2022-11-29

研究基于人群样本,在17年间测量血清t-tau、Nf-L和GFAP浓度及认知特征,纳入1327名参与者(60%为黑人,60%为女性)。结果显示t-tau年均增长4.8%(95%CI=4.0-5.6),Nf-L年均增长5.9%(95%CI=5.4-6.4);黑种人GFAP年变化高于白种人(4.4% vs 3.5%/年,p=0.028)。基线MRI特征与生物标志物纵向变化相关,且变化速率在临床AD组显著高于无认知障碍组;整体认知每下降1个标准差,t-tau、Nf-L和GFAP的纵向变化分别增加81%(95%CI=76-86)、113%(95%CI=105-120)和66%(95%CI=62-70)。

要点

  • 血清t-tau和Nf-L在17年间呈显著年均增长,t-tau为4.8%、Nf-L为5.9%。
  • 黑种人GFAP年变化高于白种人(4.4% vs 3.5%/年,p=0.028)。
  • 基线第三脑室体积较高与t-tau增长更快相关,白质高信号预测Nf-L增长更快。

核心结论

  • 血液生物标志物显示出与认知下降、临床AD和结构MRI特征相对应的显著纵向变化。
  • 血清生物标志物的纵向变化与多种认知内表型相关。
  • 研究提供Class II证据:血清t-tau、Nf-L和GFAP的纵向变化与65岁以上人群的认知下降和临床AD发展相关。

研究设计与样本

  • 基于人群的样本,纳入具有血样、认知功能测试和AD临床诊断的参与者。
  • 血清t-tau、Nf-L和GFAP浓度及认知特征在17年间测量。
  • 采用线性混合模型分析log10转换浓度的纵向变化,共纳入1327名参与者(60%为黑人,60%为女性)。

主要发现

  • t-tau浓度年均增长4.8%(95%CI=4.0-5.6),Nf-L年均增长5.9%(95%CI=5.4-6.4)。
  • 黑种人GFAP年变化为4.4%,白种人为3.5%(p=0.028)。
  • 基线第三脑室体积较高与t-tau浓度增长速率较高相关,白质高信号预测Nf-L增长速率较高。
  • 发展为临床AD者的t-tau、Nf-L和GFAP浓度变化速率显著高于无认知障碍者。
  • 整体认知每下降1个标准差,t-tau纵向变化增加81%(95%CI=76-86),Nf-L增加113%(95%CI=105-120),GFAP增加66%(95%CI=62-70)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Recent studies suggest the utility of blood biomarkers in detecting changes in neurodegenerative disorders. The objective of our research was to test the hypothesis that the longitudinal changes in total tau (t-tau), neurofilament light chain (Nf-L), and glial fibrillary acidic protein (GFAP) are associated with structural MRI and the development of clinical Alzheimer disease (AD) and cognitive decline. METHODS: Data came from a population-based sample with serum concentrations of t-tau, Nf-L, and GFAP and cognitive characteristics measured over 17 years. The inclusion criteria for this investigation were based on participants with blood samples, cognitive function testing, and clinical diagnosis for AD. The longitudinal changes in the serum biomarkers were examined using linear mixed models for log10-transformed concentrations. RESULTS: In 1,327 participants (60% Black participants and 60% women, the concentration of t-tau increased annually by 4.8% (95% CI = 4.0-5.6) and Nf-L by 5.9% (95% CI = 5.4-6.4). The longitudinal change in GFAP was higher among Black participants than among White participants (4.4% vs 3.5% per year, p = 0.028). Baseline MRI characteristics were associated with the longitudinal changes in serum biomarkers of clinical AD. Specifically, a higher baseline third ventricular volume was associated with a higher rate of increase in the concentration of t-tau, and white matter hyperintensities predicted a higher rate of increase in Nf-L. The rate of change in concentrations of t-tau, Nf-L, and GFAP was significantly higher among those who developed clinical AD than in those with no cognitive impairment. For each standard deviation unit decline in global cognition, longitudinal change in t-tau increased by 81% (95% CI = 76-86), Nf-L by 113% (95% CI = 105-120), and GFAP by 66% (95% CI = 62-70). DISCUSSION: Blood biomarkers showed significant longitudinal changes corresponding to cognitive decline, clinical AD, and structural MRI characteristics. Our findings show that longitudinal changes in serum biomarkers were associated with several cognitive endophenotypes. CLASSIFICATION OF EVIDENCE: The study found Class II evidence that longitudinal changes in serum t-tau, Nf-L, and GFAP were associated with cognitive decline and the development of clinical AD in people older than 65 years.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rajan KB, McAninch EA, Aggarwal NT, et al. Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample. Neurology. 2022. PMID: 36446595. doi:10.1212/WNL.0000000000201289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。